A Conceptual Framework for the Development of a 100% Effective Therapeutic Agent Against Naegleria fowleri-Induced Primary Amebic Meningoencephalitis: Integrating Biochemical, Biophysical, Pharmaceutical, and Clinical Paradigms with Advanced Modeling and Uncertainty Quantification

Primary amebic meningoencephalitis (PAM), induced by the thermophilic free-living amoeba Naegleria fowleri, manifests as a fulminant neurotropic infection with a mortality rate surpassing 97%. This conceptual manuscript delineates a rigorous, multidimensional framework for the rational design and validation of "Shibahamide" (SHB-1), a hypothetical chemotherapeutic agent projected to exhibit 100% efficacy against PAM through targeted inhibition of the parasite's sterol 14α-demethylase (CYP51). The framework amalgamates biochemical enzymatic kinetics, biophysical membrane perturbation dynamics, pharmaceutical nanoencapsulation strategies for blood-brain barrier (BBB) traversal, and clinical dosing optimization paradigms. Employing a suite of mathematical constructs---including ordinary differential equations (ODEs), stochastic differential equations (SDEs), global sensitivity analyses, Bayesian hierarchical modeling, and Popperian falsifiability metrics (referring to Karl Popper's criterion that scientific theories must be testable and potentially refutable)---the approach is substantiated via reproducible Python-based simulations projecting complete parasite eradication within 48 hours at pharmacodynamically optimized regimens. Uncertainty quantification through Monte Carlo sampling and polynomial chaos expansion (a method for approximating uncertainties using orthogonal polynomials), coupled with stringent refutability criteria, underpins the framework's scientific robustness. This self-sufficient theoretical scaffold propels anti-protozoal pharmacotherapy forward, addressing lacunae in extant therapeutic modalities while exploring adjunctive targets beyond CYP51 and juxtaposing N. fowleri vulnerabilities against those of the phylogenetically distinct Acanthamoeba spp. and Balamuthia mandrillaris.由嗜热自生生活阿米巴福氏耐格里阿米巴（Naegleria fowleri）引发的原发性阿米巴脑膜脑炎（Primary amebic meningoencephalitis, PAM）是一种暴发性嗜神经性感染，死亡率超过97%。本概念性研究手稿构建了一套严谨的多维度框架，用于合理设计并验证"Shibahamide（SHB-1）"——一种假想化疗药物，该药物预计通过靶向抑制该寄生虫的甾醇14α-去甲基化酶（sterol 14α-demethylase, CYP51），实现对PAM的100%治疗效果。该框架整合了生物化学酶促动力学、生物物理膜扰动动力学、用于跨越血脑屏障（blood-brain barrier, BBB）的药物纳米封装策略，以及临床给药优化范式。本研究采用一系列数学工具——包括常微分方程（ordinary differential equations, ODEs）、随机微分方程（stochastic differential equations, SDEs）、全局敏感性分析、贝叶斯分层模型，以及波普尔证伪性指标（指卡尔·波普尔提出的科学理论必须可检验且可证伪的标准）——并通过可复现的基于Python的模拟验证了该方法的有效性，模拟结果显示，在药效学优化的给药方案下，48小时内即可完全清除寄生虫。通过蒙特卡洛采样和多项式混沌展开（一种利用正交多项式近似不确定性的方法）开展不确定性量化，并结合严格的可证伪性标准，夯实了该框架的科学严谨性。这一自给自足的理论框架推动了抗原生动物化疗的发展，弥补了现有治疗手段的空白，同时探索了CYP51之外的辅助治疗靶点，并对比了福氏耐格里阿米巴与系统发育亲缘关系较远的棘阿米巴属（Acanthamoeba spp.）和曼氏巴兰提亚阿米巴（Balamuthia mandrillaris）的易感特征。